Biomarker Assessment for an Early Biological Diagnosis of Alzheimer’s Disease
November 12 – 09:00 – November 13 – 12:30 CET
Learning Objectives
· Understand the concordance and complementary roles of tau-PET, quantitative amyloid PET measures, and CSF Aβ42/40 in Alzheimer’s disease diagnostics.
· Recognize clinically relevant quantitative thresholds for Aβ and tau PET and understand how quantitative measures can complement expert visual interpretation, particularly in borderline cases.
· Describe the relationship between increasing Aβ burden, tau PET positivity, and clinical disease stage, and appreciate the diagnostic significance of concordant visual and quantitative tau positivity.
· Interpret the different metabolic/perfusion patterns in dementia
· Interchangeability of perfusion/FDG PET
· How to combine the FDG PET findings with tau and amyloid biomarkers
Target Audience
Early Stage Nuclear Medicine Physicians
Faculty
Speaker
SpeakerSpeaker
SpeakerSpeaker
SpeakerRegistration Details
Course Fee FREE
Course includes:
- Electronic Course Book, including all Slides
- Coffee & Lunch Breaks
Course does NOT include:
- Travel to the Venue
- Accommodation
Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.